The steroid-sensitive dermatoses pose an important medical and social problem, whose relevance is determined by the steady growth of the incidence, chronic relapsing course, and complexity of treatment choice. Application of glucocorticosteroids (GCS) that have complex anti-inflammatory, antiallergic, and antipruritic effect is the basic principle of external therapy of steroid-sensitive dermatoses. Despite the wide variety of various topical corticosteroids in the arsenal of a dermatologist, the discovery and market launch of new drug products is still relevant. Objective. This study is aimed at reviewing the literature on the modern aspects of the topical therapy of the steroid-sensitive dermatoses, the study of the investigations on the methylprednisolone aceponate (MPA), the new-generation GCS, and urea, the natural moisturizing factor. Material and methods. The work was carried out at the Ural Research Institute for Dermatology and Immunopathology, Ministry of Health of the Russian Federation. Results. The results of numerous studies showed high clinical efficacy of MPA and its safety due to the absence of halogens chlorine and fluorine, bioactivation at the focus of inflammation, minimal systemic absorption, and ease of use (once a day). Urea is another agent widely used for external treatment of chronic inflammatory dermatoses and having pronounced moisturizing, emollient, and antiseptic effect. Conclusion. The findings of investigations and practical experience in the use of the novel combined medicinal product, Komfoderm M2 cream, comprising the combination of MPA and 2% urea, have demonstrated the possibility of using this drug at the areas with thin sensitive skin (face, neck, folds) and in intermittent programs.